Sygnature Discovery

Sygnature Discovery is a world-leading integrated drug discovery Contract Research Organisation, boasting over 1000 staff representing 53 nationalities, including 900 dedicated scientists working on innovative drug discovery programmes. Established in 2004, Sygnature Discovery has a proven track record, having delivered over 40 pre-clinical compounds and 21 clinical compounds, with its scientists named on over 170 patent applications.

Sygnature Discovery partners with global pharmaceutical, biotechnology, and non-profit organizations, providing comprehensive integrated drug discovery services that span from target identification to candidate nomination. The co-located teams at Sygnature Discovery offer expertise in protein science, chemistry, computational chemistry, in vitro biology, pharmacology, DMPK, form and formulation services, and project management. Sygnature Discovery maintains a core therapeutic focus on oncology, inflammation and immunology, as well as neuroscience, metabolic diseases, respiratory, infectious diseases, and fibrotic diseases.

With locations at BioCity, Pennyfoot Street, Nottingham, NG1 1GR, GB; 245 First Street, Cambridge, Massachusetts 02142, US; 611 Gateway Blvd, Suite 120, South San Francisco, California 94080, US; and Alderley Park, Alderley Edge, England SK10 4TG, GB, Sygnature Discovery is strategically positioned to serve its global clientele. We invite the management team at Sygnature Discovery to create a customized and exclusive company showcase and product listing on our platform.